PTEN recruitment controls synaptic and cognitive function in Alzheimer's models

Nature Neuroscience

Volumn 19, Issue 3, 2016, Pages 443-453

  Knafo, Shira ^a,b,c   Sánchez Puelles, Cristina ^a   Palomer, Ernest ^a   Delgado, Igotz ^b   Draffin, Jonathan E ^a   Mingo, Janire ^d   Wahle, Tina ^e,f   Kaleka, Kanwardeep ^g   Mou, Liping ^h   Pereda Perez, Inmaculada ⁱ   Klosi, Edvin ^j   Faber, Erik B ^j   Chapman, Heidi M ^j   Lozano Montes, Laura ^a   Ortega Molina, Ana ^k   Ordóñez Gutiérrez, Lara ^a,l   Wandosell, Francisco ^a,l   Viña, Jose ^m   Dotti, Carlos G ^a   Hall, Randy A ^h   Pulido, Rafael ^c,d   Gerges, Nashaat Z ^g   Chan, Andrew M ⁿ   Spaller, Mark R ^j   Serrano, Manuel ^k   Venero, César ⁱ   Esteban, José A ^a   more..

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b CSIC UPV Unidad de Biofisica UBF   (Spain)

^c BASQUE FOUNDATION FOR SCIENCE   (Spain)

^d BIOCRUCES BIZKAIA HEALTH RESEARCH INSTITUTE   (Spain)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f IUF LEIBNIZ RESEARCH INSTITUTE FOR ENVIRONMENTAL MEDICINE   (Germany)

^g MEDICAL COLLEGE OF WISCONSIN   (United States)

^h EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSIDAD NACIONAL DE EDUCACIÓN A DISTANCIA   (Spain)

^j NORRIS COTTON CANCER CENTER   (United States)

^k Centro Nacional de Investigaciones Oncológicas   (Spain)

^l CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^m UNIVERSITY OF VALENCIA   (Spain)

ⁿ and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITION; CONTROLLED STUDY; DEPRESSION; ENZYME ACTIVITY; ENZYME INHIBITION; LONG TERM DEPRESSION; MOUSE; NONHUMAN; PDZ DOMAIN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SYNAPSE; TRANSGENIC MOUSE; ANIMAL; ANTAGONISTS AND INHIBITORS; COGNITIVE DEFECT; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; GENE TARGETING; GENETICS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PRIMARY CELL CULTURE; RAT; SYNAPTIC TRANSMISSION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; GENE KNOCK-IN TECHNIQUES; MICE; MICE, TRANSGENIC; PDZ DOMAINS; PRIMARY CELL CULTURE; PTEN PHOSPHOHYDROLASE; RATS; SYNAPTIC TRANSMISSION;

EID: 84959140220     PISSN: 10976256     EISSN: 15461726     Source Type: Journal    
DOI: 10.1038/nn.4225     Document Type: Article

References (52)

1. Terry, R.D. et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30, 572-580 (1991).
2. Selkoe, D.J. Alzheimer's disease is a synaptic failure. Science 298, 789-791 (2002).
3. Jack, C.R. Jr. et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain 133, 3336-3348 (2010).
4. Selkoe, D.J. Resolving controversies on the path to Alzheimer's therapeutics. Nat. Med. 17, 1060-1065 (2011).
5. Li, S. et al. Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 62, 788-801 (2009).
6. Hsieh, H. et al. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 52, 831-843 (2006).
7. Shankar, G.M. et al. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 27, 2866-2875 (2007).
8. Shankar, G.M. et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14, 837-842 (2008).
9. Walsh, D.M. et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539 (2002).
10. Cullen, W.K., Wu, J., Anwyl, R. & Rowan, M.J. beta-Amyloid produces a delayed NMDA receptor-dependent reduction in synaptic transmission in rat hippocampus. Neuroreport 8, 87-92 (1996).
11. Lambert, M.P. et al. Diffusible, nonfbrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA 95, 6448-6453 (1998).
12. Man, H.Y. et al. Activation of PI3-kinase is required for AMPA receptor insertion during LTP of mEPSCs in cultured hippocampal neurons. Neuron 38, 611-624 (2003).
13. Peineau, S. et al. LTP inhibits LTD in the hippocampus via regulation of GSK3beta. Neuron 53, 703-717 (2007).
14. Arendt, K.L. et al. PIP3 controls synaptic function by maintaining AMPA receptor clustering at the postsynaptic membrane. Nat. Neurosci. 13, 36-44 (2010).
15. Jurado, S. et al. PTEN is recruited to the postsynaptic terminal for NMDA receptor-dependent long-term depression. EMBO J. 29, 2827-2840 (2010).
16. Holcomb, L. et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 4, 97-100 (1998).
17. Rosivatz, E. et al. A small molecule inhibitor for phosphatase and tensin homologue deleted on chromosome 10 (PTEN). ACS Chem. Biol. 1, 780-790 (2006).
18. Jan, A., Hartley, D.M. & Lashuel, H.A. Preparation and characterization of toxic Abeta aggregates for structural and functional studies in Alzheimer's disease research. Nat. Protoc. 5, 1186-1209 (2010).
19. Selkoe, D.J. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav. Brain Res. 192, 106-113 (2008).
20. Welsby, P.J., Rowan, M.J. & Anwyl, R. Beta-amyloid blocks high frequency stimulation induced LTP but not nicotine enhanced LTP. Neuropharmacology 53, 188-195 (2007).
21. Klyubin, I. et al. Soluble Arctic amyloid beta protein inhibits hippocampal long-term potentiation in vivo. Eur. J. Neurosci. 19, 2839-2846 (2004).
22. Wang, Q., Walsh, D.M., Rowan, M.J., Selkoe, D.J. & Anwyl, R. Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J. Neurosci. 24, 3370-3378 (2004).
23. Chen, Q.S., Wei, W.Z., Shimahara, T. & Xie, C.W. Alzheimer amyloid beta-peptide inhibits the late phase of long-term potentiation through calcineurin-dependent mechanisms in the hippocampal dentate gyrus. Neurobiol. Learn. Mem. 77, 354-371 (2002).
24. Ortega-Molina, A. et al. Pten positively regulates brown adipose function, energy expenditure, and longevity. Cell Metab. 15, 382-394 (2012).
25. Gerges, N.Z., Brown, T.C., Correia, S.S. & Esteban, J.A. Analysis of Rab protein function in neurotransmitter receptor traffcking at hippocampal synapses. Methods Enzymol. 403, 153-166 (2005).
26. Kamenetz, F. et al. APP processing and synaptic function. Neuron 37, 925-937 (2003).
27. Citron, M., Teplow, D.B. & Selkoe, D.J. Generation of amyloid beta protein from its precursor is sequence specifc. Neuron 14, 661-670 (1995).
28. Jacobsen, J.S. et al. Early-onset behavioral and synaptic defcits in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 103, 5161-5166 (2006).
29. Knafo, S. et al. Widespread changes in dendritic spines in a model of Alzheimer's disease. Cereb. Cortex 19, 586-592 (2009).
30. Wei, W. et al. Amyloid beta from axons and dendrites reduces local spine number and plasticity. Nat. Neurosci. 13, 190-196 (2010).
31. Spires, T.L. et al. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J. Neurosci. 25, 7278-7287 (2005).
32. Maehama, T. & Dixon, J.E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3, 4, 5-trisphosphate. J. Biol. Chem. 273, 13375-13378 (1998).
33. He, J. et al. Proteomic analysis of beta1-adrenergic receptor interactions with PDZ scaffold proteins. J. Biol. Chem. 281, 2820-2827 (2006).
34. Wu, Y. et al. Interaction of the tumor suppressor PTEN/MMAC with a PDZ domain of MAGI3, a novel membrane-associated guanylate kinase. J. Biol. Chem. 275, 21477-21485 (2000).
35. Wu, X. et al. Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. Proc. Natl. Acad. Sci. USA 97, 4233-4238 (2000).
36. von Stein, W., Ramrath, A., Grimm, A., Müller-Borg, M. & Wodarz, A. Direct association of Bazooka/PAR-3 with the lipid phosphatase PTEN reveals a link between the PAR/aPKC complex and phosphoinositide signaling. Development 132, 1675-1686 (2005).
37. Cissé, M. et al. Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature 469, 47-52 (2011).
38. Jo, J. et al. A(1-42) inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3β. Nat. Neurosci. 14, 545-547 (2011).
39. Hongpaisan, J., Sun, M.K. & Alkon, D.L. PKC ε activation prevents synaptic loss, Aβ elevation, and cognitive defcits in Alzheimer's disease transgenic mice. J. Neurosci. 31, 630-643 (2011).
40. Ma, T. et al. Dysregulation of the mTOR pathway mediates impairment of synaptic plasticity in a mouse model of Alzheimer's disease. PLoS One 5, e12845 (2010).
41. Kwak, Y.D. et al. NO signaling and S-nitrosylation regulate PTEN inhibition in neurodegeneration. Mol. Neurodegener. 5, 49 (2010).
42. Talbot, K. et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J. Clin. Invest. 122, 1316-1338 (2012).
43. Zhang, X. et al. Tumor-suppressor PTEN affects tau phosphorylation, aggregation, and binding to microtubules. FASEB J. 20, 1272-1274 (2006).
44. Griffn, R.J. et al. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. J. Neurochem. 93, 105-117 (2005).
45. Pei, J.J. et al. Role of protein kinase B in Alzheimer's neurofbrillary pathology. Acta Neuropathol. 105, 381-392 (2003).
46. Freude, S. et al. Neuronal IGF-1 resistance reduces Abeta accumulation and protects against premature death in a model of Alzheimer's disease. FASEB J. 23, 3315-3324 (2009).
47. Cohen, E. et al. Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. Cell 139, 1157-1169 (2009).
48. De Felice, F.G., Lourenco, M.V. & Ferreira, S.T. How does brain insulin resistance develop in Alzheimer's disease? Alzheimers Dement. 10 (suppl. 1) S26-S32 (2014).
49. Ehrengruber, M.U. et al. Recombinant Semliki Forest virus and Sindbis virus effciently infect neurons in hippocampal slice cultures. Proc. Natl. Acad. Sci. USA 96, 7041-7046 (1999).
50. Torres, J. et al. Heterogeneous lack of expression of the tumour suppressor PTEN protein in human neoplastic tissues. Eur. J. Cancer 37, 114-121 (2001).
51. Valiente, M. et al. Binding of PTEN to specifc PDZ domains contributes to PTEN protein stability and phosphorylation by microtubule-associated serine/threonine kinases. J. Biol. Chem. 280, 28936-28943 (2005).
52. Hood, C.A. et al. Fast conventional Fmoc solid-phase peptide synthesis with HCTU. J. Pept. Sci. 14, 97-101 (2008).